A milestone has successfully been achieved using NLAB SilicaTM as the delivery vehicle for biologics formulation. Peptide growth factors were encapsulated in NLAB SilicaTM to enable controlled and sustained release upon transplantation in vivo. The controlled delivery of growth factors resulted in improved differentiation and survival of co-transplanted neuron stem cells in mouse models of spinal cord injury and other neuronal diseases. These findings have the potential of revolutionizing the treatment of neurodegenerative disorders. Nanologica is presently pursuing results from this research towards Amyotrophic lateral sclerosis (ALS) therapy.